Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 12/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631381 | 0.88 | NR4A2 (0.70) | NR4A2CREBBPGAAMAPTMAP2K1 | |
| SCHEMBL1007089 | 0.84 | NR4A2 (0.50) | NR4A2CREBBPHPGDCYP2C19MEN1 | |
| SCHEMBL6521138 | 0.84 | GABRA1 (0.60) | NR4A2GAAHPGDCYP2C19MEN1 | |
| SCHEMBL27365216 | 0.83 | NR4A2 (0.72) | NR4A2CREBBPGAAHPGDMEN1 | |
| SCHEMBL4240354 | 0.83 | NR4A2 (1.00) | NR4A2CREBBPMEN1MITFLMNA | |
| SCHEMBL6488517 | 0.82 | PBRM1 (0.59) | NR4A2HPGDCYP2C19MEN1MITF | |
| SCHEMBL1519903 | 0.82 | F7 (0.64) | NR4A2GAAHPGDCYP2C19MEN1 | |
| SCHEMBL4242189 | 0.81 | NR4A2 (1.00) | NR4A2CREBBPPYGLF7F3 | |
| SCHEMBL15300704 | 0.81 | NR4A2 (0.70) | NR4A2CREBBPMEN1MITFLMNA | |
| SCHEMBL6635171 | 0.81 | HPGD (0.48) | NR4A2CREBBPHPGDCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| CN-1723022-A | inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 | STERIX LTD (GB) | 2006-01-18 | — | — | CN | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | NR4A2 169/4885CREBBP 2269/4885GAA 4414/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | NR4A2 21/4885CREBBP 1533/4885GAA 4874/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | NR4A2 21/4885CREBBP 1533/4885GAA 4874/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | NR4A2 26/4885CREBBP 2810/4885GAA 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.